{"name":"OPKO Health","slug":"opko","ticker":"OPK","exchange":"NASDAQ","domain":"opko.com","description":"OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol \"OPK\".","hq":"Miami, FL","founded":0,"employees":"2275","ceo":"Phillip Frost","sector":"Diagnostics / Specialty Pharma","stockPrice":1.11,"stockChange":0,"stockChangePercent":0,"marketCap":"$838M","metrics":{"revenue":606879000,"revenueGrowth":-17.2,"grossMargin":14.9,"rdSpend":124033000,"netIncome":-225680000,"cash":331862016,"dividendYield":0,"peRatio":-3.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Rayaldee patent cliff ($100M at risk)","drug":"Rayaldee","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"Calcifediol Oral Capsule","genericName":"Calcifediol Oral Capsule","slug":"calcifediol-oral-capsule","indication":"Other","status":"marketed"},{"name":"Calcifediol Oral Product","genericName":"Calcifediol Oral Product","slug":"calcifediol-oral-product","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease","status":"marketed"},{"name":"Cohort 1 CTAP101 Capsules - 90µg","genericName":"Cohort 1 CTAP101 Capsules - 90µg","slug":"cohort-1-ctap101-capsules-90-g","indication":"Treatment of osteoporosis in postmenopausal women","status":"phase_2"},{"name":"Cohort 1 CTAP101 Capsules- 60µg","genericName":"Cohort 1 CTAP101 Capsules- 60µg","slug":"cohort-1-ctap101-capsules-60-g","indication":"Other","status":"phase_2"},{"name":"Cohort 1 Matching Sugar Capsule","genericName":"Cohort 1 Matching Sugar Capsule","slug":"cohort-1-matching-sugar-capsule","indication":"Other","status":"phase_2"},{"name":"Cohort 2 CTAP101 Capsules - 30µg","genericName":"Cohort 2 CTAP101 Capsules - 30µg","slug":"cohort-2-ctap101-capsules-30-g","indication":"Osteoporosis","status":"phase_2"},{"name":"Rayaldee","genericName":"Rayaldee","slug":"rayaldee","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CTAP101 Capsules","genericName":"CTAP101 Capsules","slug":"ctap101-capsules","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CTA018 cream","genericName":"CTA018 cream","slug":"cta018-cream","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"CTAP101 Capsules","genericName":"CTAP101 Capsules","slug":"ctap101-capsules","phase":"phase_3","mechanism":"CTAP101 is a capsule formulation of calcitriol (active vitamin D) that enhances calcium absorption and regulates calcium-phosphate metabolism.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease","Vitamin D deficiency-related mineral metabolism disorders"],"catalyst":""},{"name":"CTA018 cream","genericName":"CTA018 cream","slug":"cta018-cream","phase":"phase_2","mechanism":"CTA018 cream is a topical corticosteroid used to treat inflammatory skin conditions.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"Calcifediol Oral Capsule","genericName":"Calcifediol Oral Capsule","slug":"calcifediol-oral-capsule","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calcifediol Oral Product","genericName":"Calcifediol Oral Product","slug":"calcifediol-oral-product","phase":"marketed","mechanism":"Calcifediol is an active vitamin D metabolite that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis and modulate immune function.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease","Hypocalcemia in patients with hypoparathyroidism"],"catalyst":""},{"name":"Cohort 1 CTAP101 Capsules - 90µg","genericName":"Cohort 1 CTAP101 Capsules - 90µg","slug":"cohort-1-ctap101-capsules-90-g","phase":"phase_2","mechanism":"CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue.","indications":["Treatment of osteoporosis in postmenopausal women"],"catalyst":""},{"name":"Cohort 1 CTAP101 Capsules- 60µg","genericName":"Cohort 1 CTAP101 Capsules- 60µg","slug":"cohort-1-ctap101-capsules-60-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cohort 1 Matching Sugar Capsule","genericName":"Cohort 1 Matching Sugar Capsule","slug":"cohort-1-matching-sugar-capsule","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cohort 2 CTAP101 Capsules - 30µg","genericName":"Cohort 2 CTAP101 Capsules - 30µg","slug":"cohort-2-ctap101-capsules-30-g","phase":"phase_2","mechanism":"CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue.","indications":["Osteoporosis"],"catalyst":""},{"name":"Rayaldee","genericName":"Rayaldee","slug":"rayaldee","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"OPKO Health Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"OPKO Health reported its fourth quarter and full year 2023 financial results, with revenue of $143.8 million and a net loss of $123.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"OPKO Health Announces Collaboration with Pfizer to Develop and Commercialize Rayaldee in Japan","summary":"OPKO Health announced a collaboration with Pfizer to develop and commercialize Rayaldee in Japan.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves OPKO Health's 4Kscore Test for Prostate Cancer","summary":"The FDA approved OPKO Health's 4Kscore test for prostate cancer, a blood test that helps determine the risk of aggressive prostate cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOaGpPU2dXempxY0FzQkZMbFd5ZFV3Vy0yTGpocXVUY05uR1JDcjlCRTlwUDdjOWZvUnBJZUNIa1V1MzNlQXBmZUF5WWNEemRVaDR2LTdnWG01VHg5RnNiTXg3UVBvQ1JvejRMVUZBVHJLbW1fck1iTDVwSHJqSTJFSVd0ODA0NVE5bVlEdkVMSFR0N0lMa1RwMHlXMm5qSzRDanJiaTcwbWlNbEtYQmQyelFLWU1EalFYQmp2SktkNA?oc=5","date":"2026-03-29","type":"pipeline","source":"AD HOC NEWS","summary":"OPKO Health Inc Stock: Business Model, Growth Drivers, and Key Investor Considerations in Diagnostic - AD HOC NEWS","headline":"OPKO Health Inc Stock: Business Model, Growth Drivers, and Key Investor Considerations in Diagnostic","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxObEs1c25FRzhFeFUyZGhCWHdtOUEtZXYtVTJqdDZ2ai1CcThFNU5abDhkWEVwM1VIZjRHdS0teHl2bENiSm9hV2xqZTFaRjlWOUlkSFc3NTNwWE1xcHNUc3hfajZMWVJKUmJTdFJ4bmdCaV9XSURjWmFZQy1YRlN0YU92dHJFTTFvR192QTE5Rlp1Nm9mZFRfazJQcVloZHNkZm1QTjFqU1dkMW5UNXdwT0FFejY4R2MtU1E?oc=5","date":"2026-02-27","type":"earnings","source":"TradingView","summary":"OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts - TradingView","headline":"OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts","sentiment":"positive"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNMWp6Z0hrdDE3cXRtMWFyVWdOSlEtZmhic3BxNHJSY0hmMjJMR2ZMOXVsaFRNazFtWVZZemZ1YTRmU2UwUW83ZjJoTnNhVTFENkVneFA1cHN1bDJTNmZOb1g0YnBucXhVNWlocFAxY1ZnZ0RfZzBLY3BMaGFGMTJVem1zNnFJYmpQNmt1S2daUmtjYXd2NHVJeWV3?oc=5","date":"2026-01-27","type":"pipeline","source":"Seeking Alpha","summary":"OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha","headline":"OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5zUEZ3OGtHdkZncF80NkZIOXVlTFNSVFlqNFJqNEZfMWdSd1FPcGNOcElCU2hMd05MWVBZSF9uTnhCWWlkWXNkNEVqUk1GS2g5d0c0anRKNXU4amFjY29uaUdVS3dLWnVPWll0dmprSjVIT3RlQkZvR0JXQQ?oc=5","date":"2025-10-30","type":"deal","source":"Yahoo Finance","summary":"Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Yahoo Finance","headline":"Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals","sentiment":"neutral"},{"date":"2025-10-29","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9ZeXpPRlJnUUFFUFd6U1Z6SXdSdjI5MFFnQzYtbkg3ODZyUFZrZzN1MnlZM3pfV1pzX2ZZbUlMZEN6VjByVTRSNW1HbTFiWFBzZVgycS1IdTItbmYzMmpqeVBLel9vUUVNMjBQeVVqR1FGNWpuNzRrVGk2VW9jMjA?oc=5","date":"2025-08-17","type":"pipeline","source":"Yahoo Finance","summary":"OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics - Yahoo Finance","headline":"OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNX0Y5VmQwT25xNDZOd1ZmUGdKSURUNkVrUUxmQXc5RzB5c1h5d1VKenNTRThaQ1VZRWstaXRCdzdZMng4QTFEa0x1OHFpaG5KTTRGOERDMGxiQl9mS0JnOGE1MktmRWpzYjk4eTZWeHRwVkl2NGhxVjA2NnBWQThjUmFhYkdsRGFRZmhaYVFpSWZfaEF6eEdxNkZGX3Q4cU4tQjgzUUZRaFNzeXdKLXVKTEZxdVlEVGVvOUtYdnhXQV9JMzR5dUlRTHMwTC1NYXd2R1FNVkVYdE9PTjhoNjdTRHJnUWw?oc=5","date":"2025-07-31","type":"earnings","source":"OPKO Health, Inc.","summary":"OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc.","headline":"OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc.","sentiment":"neutral"},{"date":"2025-07-31","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-07-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPaXlWVW5Kcng3a1ZiY3MwaUpwc3JSbWpDSGhuNkZuLWhKMjJxYTZ3R1h3WVpLdE44bTVEUzVLaGtlOGhXaE5vTGNfOEhaNmxyZU9QU0hJRTNTMHJobGZDQmg2dlhUYjJRYTdFNkpvS1lib0xBS0ZZN0kxaDdSWXZiWEtybG5iMFdZX2JDNGJRRWJlRi1HcEFnNnRfTDkzcjNGeWc?oc=5","date":"2025-06-11","type":"deal","source":"Seeking Alpha","summary":"OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha","headline":"OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK)","sentiment":"neutral"}],"patents":[{"drugName":"Rayaldee","drugSlug":"calcitriol","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":9,"phaseCounts":{"phase_3":1,"phase_2":5,"marketed":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["LabCorp","Quest Diagnostics","Exact Sciences"],"therapeuticFocus":["Diagnostics","Specialty Pharma"],"financials":{"source":"sec_edgar+yahoo","revenue":606879000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":606879000,"period":"2025-12-31"},{"value":148451000,"period":"2025-12-31"},{"value":151669000,"period":"2025-09-30"},{"value":156807000,"period":"2025-06-30"},{"value":149952000,"period":"2025-03-31"}],"grossProfit":205940000,"grossProfitHistory":[{"period":"2025-12-31","value":205940000},{"period":"2024-12-31","value":218510000},{"period":"2023-12-31","value":318127000},{"period":"2022-12-31","value":288219000}],"rdSpend":124033000,"rdSpendHistory":[{"period":"2025-12-31","value":124033000},{"period":"2024-12-31","value":105214000},{"period":"2023-12-31","value":89593000},{"period":"2022-12-31","value":73887000}],"sgaSpend":223002000,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-225680000,"netIncomeHistory":[{"period":"2025-12-31","value":-225680000},{"period":"2024-12-31","value":-53224000},{"period":"2023-12-31","value":-188863000},{"period":"2022-12-31","value":-328405000}],"eps":-0.3,"epsHistory":[{"period":"2025-12-31","value":-0.3},{"period":"2024-12-31","value":-0.08},{"period":"2023-12-31","value":-0.25},{"period":"2022-12-31","value":-0.46}],"cash":369074000,"cashHistory":[{"period":"2025-12-31","value":369074000},{"period":"2024-12-31","value":431936000},{"period":"2023-12-31","value":95881000},{"period":"2022-12-31","value":153191000}],"totalAssets":1931944000,"totalLiabilities":663985000,"totalDebt":396782000,"equity":1267959000,"operatingCashflow":-178542000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-178542000},{"period":"2024-12-31","value":-183489000},{"period":"2023-12-31","value":-28197000},{"period":"2022-12-31","value":-95189000}],"capex":-12278000,"capexHistory":[{"period":"2025-12-31","value":-12278000},{"period":"2024-12-31","value":-25010000},{"period":"2023-12-31","value":-16275000},{"period":"2022-12-31","value":-24578000}],"freeCashflow":-190820000,"dividendsPaid":null,"buybacks":-47040000,"employees":2275,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":48607000,"ebit":-50017000,"ebitda":-27816000,"period":"2026-03-31","revenue":124196000,"epsBasic":-0.07,"netIncome":-54848000,"rdExpense":29199000,"epsDiluted":-0.07,"grossProfit":45755000,"operatingIncome":-51017000},{"sga":50515000,"ebit":-35591000,"ebitda":-13218000,"period":"2025-12-31","revenue":148450000,"epsBasic":-0.04,"netIncome":-31257000,"rdExpense":32772000,"epsDiluted":-0.04,"grossProfit":64025000,"operatingIncome":-38317000},{"sga":53804000,"ebit":52789000,"ebitda":75529000,"period":"2025-09-30","revenue":151669000,"epsBasic":0.03,"netIncome":21631000,"rdExpense":30078000,"epsDiluted":0.03,"grossProfit":49893000,"operatingIncome":-53520000},{"sga":59597000,"ebit":-92193000,"ebitda":-69166000,"period":"2025-06-30","revenue":156807000,"epsBasic":-0.19,"netIncome":-148441000,"rdExpense":30342000,"epsDiluted":-0.19,"grossProfit":49402000,"operatingIncome":-59981000},{"sga":59086000,"ebit":-57908000,"ebitda":-34421000,"period":"2025-03-31","revenue":149952000,"epsBasic":-0.1,"netIncome":-67613000,"rdExpense":30841000,"epsDiluted":-0.1,"grossProfit":42620000,"operatingIncome":-67168000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.11,"previousClose":1.11,"fiftyTwoWeekHigh":1.6,"fiftyTwoWeekLow":0.98,"fiftyTwoWeekRange":"0.98 - 1.6","fiftyDayAverage":1.16,"twoHundredDayAverage":1.31,"beta":1.41,"enterpriseValue":903217408,"forwardPE":-3.5,"priceToBook":0.66,"priceToSales":1.44,"enterpriseToRevenue":1.55,"enterpriseToEbitda":-8.03,"pegRatio":0,"ebitda":-112493000,"ebitdaMargin":-19.4,"freeCashflow":-36094624,"operatingCashflow":-163298000,"totalDebt":396927008,"debtToEquity":33,"currentRatio":3.61,"returnOnAssets":-6.4,"returnOnEquity":-16.9,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":3.76,"targetHighPrice":8.5,"targetLowPrice":1.3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":49.5,"institutionHeldPercent":27.3,"sharesOutstanding":755092256,"floatShares":332323653,"sharesShort":33763628,"shortRatio":14.51,"shortPercentOfFloat":4.5,"epsTrailing":-0.27,"epsForward":-0.32,"revenuePerShare":0.75,"bookValue":1.67,"officers":[{"age":89,"name":"Dr. Phillip  Frost M.D., Ph.D.","title":"Chairman of the Board & CEO"},{"age":78,"name":"Dr. Jane H. Hsiao M.B.A., Ph.D.","title":"Vice Chairman of the Board & Chief Technical Officer"},{"age":74,"name":"Dr. Elias Adam Zerhouni M.D.","title":"President & Vice Chairman of the Board"},{"age":47,"name":"Mr. Adam E. Logal","title":"Senior VP, CFO, Chief Accounting Officer & Treasurer"},{"age":65,"name":"Mr. Steven D. Rubin Esq., J.D.","title":"Executive VP of Administration & Director"},{"age":null,"name":"Dr. Akhtar  Ashfaq FACP, FASN, M.D.","title":"Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal"},{"age":70,"name":"Dr. Gary J. Nabel M.D., Ph.D.","title":"Chief Innovation Officer & Director"},{"age":null,"name":"Mr. Giovanni  Abbadessa M.D., Ph.D.","title":"Chief Medical Officer of ModeX"}],"industry":"Diagnostics & Research","irWebsite":"http://investor.opko.com/","website":"https://www.opko.com","phone":"305 575 4100"}}